Rezolute(US:RZLT) Globenewswire·2025-12-19 15:08Core Viewpoint - Rezolute, Inc. experienced a significant decline in stock value following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug, which failed to meet primary and key secondary endpoints [3][4]. Group 1: Company Performance - Rezolute's shares dropped sharply on December 11, 2025, with a decline from approximately $10.94 to an intraday low of around $0.90, representing an approximate 85-90% decrease [4]. - The Phase 3 sunRIZE clinical trial for ersodetug aimed at treating congenital hyperinsulinism did not achieve statistically significant reductions in hypoglycemia events compared to placebo [3]. Group 2: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute for investors who suffered significant losses due to the stock's decline [1][2].